|
Outcome
|
Subgroup
|
Number of trials
|
Number of participants
|
RR (95% CI)
|
Phetero
|
|---|
|
AF
|
Overall
|
21
|
51,193
|
0.82 (0.70–0.96)
| |
|
Baseline condition
|
DM
|
16
|
44,896
|
0.84 (0.71–1.00)
|
0.63
|
|
CKD
|
3
|
1474
|
0.93 (0.18–4.68)
|
|
HF
|
2
|
4823
|
0.65 (0.40–1.07)
|
|
ASCVD
|
No ASCVD
|
18
|
43,114
|
0.79 (0.67–0.94)
|
0.16
|
|
ASCVD present
|
3
|
8079
|
1.23 (0.69–2.19)
|
|
SGLT2i agent
|
Canagliflozin
|
6
|
16,378
|
0.90 (0.65–1.26)
|
0.39
|
|
Dapagliflozin
|
7
|
25,090
|
0.75 (0.61–0.91)
|
|
Empagliflozin
|
7
|
9258
|
1.19 (0.68–2.08)
|
|
Ertugliflozin
|
1
|
467
|
1.48 (0.06–36.08)
|
|
Follow-up duration
|
≤ 1 year
|
11
|
4916
|
0.82 (0.69–0.97)
|
0.90
|
|
> 1 year
|
10
|
42,677
|
0.82 (0.70–0.96)
|
|
Embolic stroke
|
Overall
|
6
|
44,205
|
0.32 (0.12–0.85)
| |
|
Baseline condition
|
DM
|
4
|
38,723
|
0.32 (0.10–1.03)
|
0.99
|
|
CKD
|
1
|
4401
|
0.25 (0.01–6.21)
|
|
HF
|
1
|
4744
|
0.25 (0.03–3.20)
|
|
ASCVD
|
No ASCVD
|
5
|
37,185
|
0.37 (0.12–1.10)
|
0.53
|
|
ASCVD present
|
1
|
7020
|
0.17 (0.02–1.59)
|
|
SGLT2i agent
|
Canagliflozin
|
2
|
14,543
|
0.29 (0.03–2.77)
|
0.78
|
|
Dapagliflozin
|
3
|
21,904
|
0.43 (0.11–1.68)
|
|
Empagliflozin
|
4
|
7758
|
1.19 (0.03–1.21)
|
|
Follow-up duration
|
≤ 1 year
|
1
|
738
|
0.25 (0.01–6.21)
|
0.89
|
|
> 1 year
|
5
|
43,467
|
0.32 (0.12–0.92)
|
|
AFL
|
Overall
|
9
|
45,478
|
0.83 (0.58–1.17)
| |
|
Baseline condition
|
DM
|
6
|
36,333
|
0.75 (0.52–1.09)
|
0.19
|
|
CKD
|
1
|
4401
|
1.00 (0.14–7.08)
|
|
HF
|
1
|
4744
|
2.66 (0.71–10.03)
|
|
ASCVD
|
No ASCVD
|
6
|
37,439
|
0.91 (0.55–1.48)
|
0.90
|
|
ASCVD present
|
3
|
8039
|
0.97 (0.36–2.66)
|
|
SGLT2i agent
|
Canagliflozin
|
2
|
14,543
|
1.08 (0.56–2.10)
|
0.95
|
|
Dapagliflozin
|
3
|
22,826
|
0.91 (0.28–3.00)
|
|
Empagliflozin
|
4
|
8109
|
1.14 (0.45–3.03)
|
|
Follow-up duration
|
≤ 1 year
|
2
|
1019
|
0.33 (0.01–8.20)
|
0.56
|
|
> 1 year
|
7
|
44,459
|
0.87 (0.59–1.29)
|
|
AF/AFL
|
Overall
|
22
|
49,115
|
0.82 (0.71–0.95)
| |
|
Baseline condition
|
DM
|
17
|
41,686
|
0.82 (0.70–0.97)
|
0.99
|
|
CKD
|
3
|
5606
|
0.83 (0.46–1.51)
|
|
HF
|
2
|
4823
|
0.79 (0.51–1.24)
|
|
ASCVD
|
No ASCVD
|
18
|
40,114
|
0.79 (0.68–0.93)
|
0.16
|
|
ASCVD present
|
4
|
9001
|
1.16 (0.70–1.91)
|
|
SGLT2i agent
|
Canagliflozin
|
6
|
16,378
|
0.94 (0.70–1.26)
|
0.20
|
|
Dapagliflozin
|
8
|
26,012
|
0.74 (0.62–0.89)
|
|
Empagliflozin
|
7
|
9258
|
1.21 (0.74–1.97)
|
|
Ertugliflozin
|
1
|
467
|
1.48 (0.06–36.08)
|
|
Follow-up duration
|
≤ 1 year
|
12
|
5838
|
0.73 (0.31–1.71)
|
0.78
|
|
> 1 year
|
10
|
42,677
|
0.82 (0.71–0.96)
|
|
VT
|
Overall
|
7
|
43,963
|
0.73 (0.53–0.99)
| |
|
Baseline condition
|
DM
|
4
|
34,739
|
0.90 (0.56–1.42)
|
0.50
|
|
CKD
|
1
|
2501
|
0.50 (0.05–5.50)
|
|
HF
|
2
|
4823
|
0.62 (0.41–0.95)
|
|
ASCVD
|
No ASCVD
|
6
|
36,846
|
0.77 (0.56–1.06)
|
0.30
|
|
ASCVD present
|
2
|
7117
|
0.44 (0.16–1.20)
|
|
SGLT2i agent
|
Canagliflozin
|
2
|
14,543
|
0.80 (0.28–2.32)
|
0.48
|
|
Dapagliflozin
|
3
|
22,224
|
0.82 (0.50–1.33)
|
|
Empagliflozin
|
3
|
7196
|
0.42 (0.16–1.11)
|
|
Follow-up duration
|
≤ 1 year
|
3
|
496
|
0.98 (0.10–9.29)
|
0.79
|
|
> 1 year
|
5
|
43,647
|
0.72 (0.53–0.99)
|
|
Cardiac arrest
|
Overall
|
7
|
44,751
|
0.83 (0.61–1.14)
| |
|
Baseline condition
|
DM
|
4
|
34,868
|
0.74 (0.42–1.30)
|
0.93
|
|
CKD
|
2
|
5139
|
0.72 (0.25–2.08)
|
|
HF
|
1
|
4744
|
0.90 (0.37–2.21)
|
|
ASCVD
|
No ASCVD
|
6
|
37,731
|
0.92 (0.66–1.30)
|
0.12
|
|
ASCVD present
|
1
|
7020
|
0.46 (0.20–1.03)
|
|
SGLT2i agent
|
Canagliflozin
|
2
|
14,543
|
0.85 (0.46–1.52)
|
0.44
|
|
Dapagliflozin
|
3
|
22,450
|
0.88 (0.44–1.75)
|
|
Empagliflozin
|
2
|
7758
|
0.48 (0.22–1.04)
|
|
Follow-up duration
|
≤ 1 year
|
1
|
738
|
0.76 (0.05–12.13)
|
0.97
|
|
> 1 year
|
6
|
44,013
|
0.81 (0.56–1.16)
|
- AF atrial fibrillation, AFL atrial flutter, VT ventricular tachycardia, RR risk ratio, 95% CI 95% confidence interval, Phetero P-value for between-subgroup heterogeneity, DM diabetes mellitus, CKD chronic kidney disease, HF heart failure, ASCVD atherosclerotic cardiovascular disease
